This is the authors' abstract. We don't add key points for this paper.
An integrated strategy was proposed for the rapid screening of pancreatic lipase inhibitors from Sibiraea angustata (Rehd.) Hand.-Mazz. (S. angustata) leaves based on affinity ultrafiltration, high-performance liquid chromatography-quadrupole time-of-flight mass spectrometry (HPLC-QTOFMS), molecular docking, targeted separation and in vitro experimental verification. A total of fifteen target compounds, including five flavonoids, one phenylpropanol glycoside and nine terpenoids, had been screened as pancreatic lipase inhibitors from the ethyl acetate and n-butanol fractions of S. angustata leaves. Among these target compounds, thirteen of them are reported as pancreatic lipase inhibitors for the first time. Hyperin, quercetin-3,4′-diglucoside and peltatoside showed stronger binding abilities with pancreatic lipase with ΔG values −9.9, −10.2 and −9.2 kcal/mol while the IC50 values were 0.987 ± 0.079, 0.718 ± 0.054 and 0.916 ± 0.069 mmol/L, respectively. The target compounds quercetin-3,4′-diglucoside and peltatoside were separated with purities higher than 98% using macroporous resin and preparative chromatography.
No takes yet. Share an insight, caveat, or question.
Song et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: